This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal squamous cell carcinoma (ESCC). The primary research objectives are to increase the R0 resection rate in such patients, thereby reducing the recurrence rate and improving overall survival (OS), as well as avoiding adverse reactions associated with radiotherapy.
None
Patients with cervical esophageal squamous cell carcinoma.
Patients with distant metastasis.
Patients with nearly complete esophageal obstruction confirmed by endoscopy who require interventional therapy for decompression.
Patients with prior placement of esophageal or tracheal stents.